A meta-analysis of serum osteocalcin level in postmenopausal osteoporotic women compared to controls

Zhongyu Liu†, Ruiqiang Chen†, Yutong Jiang, Yang Yang, Lei He, Chunxiao Luo, Jianwen Dong* and Limin Rong*

Abstract

Background: Circulatory osteocalcin (OC) has been widely used as a biomarker to indicate bone turnover status in postmenopausal osteoporosis (PMO). However, the change of serum OC (sOC) level in PMO cases compared to postmenopausal controls remains controversial.

Methods: We searched the online database of PubMed and Cochrane Library. A meta-analysis of case-control studies was performed to compare the pooled sOC level between PMO patients and postmenopausal controls. Subgroup analysis according to potential confounding factors (different OC molecules and regions of the study population) was also performed.

Results: Ten case-control studies with 1577 postmenopausal women were included in this meta-analysis. We found no significant difference in the pooled sOC level [mean difference (MD) = 1.84, 95% confidence interval (CI): (−1.49, 5.16), p = 0.28] between PMO patients and controls. Subgroup analysis also revealed no significant difference in intact OC [MD = 1.76, 95% CI: (−1.71, 5.23), p = 0.32] or N-terminal mid-fragment of the OC molecule [MD = 0.67, 95% (−5.83, 7.18), p = 0.84] between groups. For different regions, no significant difference in sOC was found in Asian population between cases and controls [MD = −0.06, 95% (−6.02, 5.89), p = 0.98], while the pooled sOC level was significantly higher in European PMO cases than controls [MD = 3.15, 95% (0.90, 5.39), p = 0.006].

Conclusions: Our analysis revealed no significant difference in sOC level between PMO cases and controls according to all the current eligible studies. OC molecules are quite heterogeneous in the circulation and can be influenced by glucose metabolism. Therefore, sOC is currently not a good indicator for the high bone turnover status in PMO. More trials with standardized methodologies for the evaluation of circulatory OC are awaited to update our current findings.

Keywords: Osteocalcin, Bone turnover marker, Postmenopausal osteoporosis, Meta-analysis
on the other hand it can also enter the circulation from osteoclastic bone matrix degradation during bone resorption. Therefore, circulatory OC may come from both bone formation and bone resorption [5, 6] and serum osteocalcin (sOC) level may theoretically increase in PMO, which is characterized by high bone turnover status with both increased bone formation and bone resorption.

Although serum osteocalcin (sOC) has been widely used as a bone turnover marker to indicate the high bone turnover status in PMO [7–9], the change of sOC level in PMO cases compared to controls remains controversial. Some of the previous studies have found a higher sOC level in PMO patients than age-matched controls, which is consistent with the high bone turnover status in PMO cases [10–12]. Meanwhile, there are also studies reporting the same or even lower sOC level in PMO cases than controls. In 2012, Biver et al. [13] performed a meta-analysis to compare several bone turnover markers between osteoporotic cases and controls and found no significant difference in sOC, which is so far the only pooled evidence of sOC change in OP. However, they included all types of osteoporosis where bone metabolic patterns might be quite heterogeneous. More studies have emerged since then and the pooled evidence of sOC change in PMO cases compared to controls is needed.

To obtain the evidence, we performed a meta-analysis of the available case-control studies to compare the sOC level between PMO patients and age-matched postmenopausal controls.

Methods
We followed the Preferred Reporting Item for Systemic Review and Meta-analysis (PRISMA) [14, 15] and performed this meta-analysis based on a protocol, according to the recommendations of the Cochrane Collaboration.

Data sources and search strategies
We searched PubMed and Cochrane Library online for all the available case-control studies published up to (12 October 2018), without restriction to regions and languages. Detailed strategy was: (“biological markers”[Title/Abstract] OR “turnover markers”[Title/Abstract] OR “osteocalcin”[Title/Abstract] OR “BGP”[Title/Abstract]) AND (“postmenopausal osteoporosis”[Title/Abstract] OR “type I osteoporosis”[Title/Abstract]). Conventional searches were supplemented by manual searches of the reference lists of all the relevant studies, review articles and conference abstracts.

Inclusion and exclusion criteria
Studies were included if they met the following inclusion criteria: 1.case-control study design; 2.patients in the case group were diagnosed of PMO, according to the diagnostic criteria recommended by WHO [16]; 3.participants in the control group were age and sex matched with cases; 4.sOC level was reported. Studies were excluded if they met the following exclusion criteria: 1.secondary osteoporosis, or under any circumstance that bone turnover or sOC level might be affected (e.g., hyperparathyroidism, diabetes mellitus, liver disease, renal insufficiency, anti-osteoporotic therapy, and long-term corticosteroid therapy); 2.studies including males or non-postmenopausal females.

Study selection and data extraction
Two literature reviewers evaluated the eligibility of potential titles and abstracts independently. Included studies were reassessed as full text by inclusion and exclusion criteria. Disagreement was solved by discussion. Further adjudication of a third reviewer was performed if the disagreement remained. The following data were then extracted from each eligible study: the first author’s name, year of publication, demographic information (age, region, and number of people in case and control groups), sampling condition, manufacturer of the OC assay kit, target fragment of the sOC molecule and sOC level.

Quality assessment of the included studies
Assessment to the risk of bias of case-control studies was performed using the Newcastle-Ottawa Scale (NOS) [17], as recommended by Cochrane Collaboration. A score of 0–9 was allocated to each study. Studies achieving six or more points were considered of high quality, which is essential for a high-level pooled evidence. Again, two reviewers independently evaluated the included studies and disagreement was solved by discussion. Further adjudication of a third reviewer was performed if the disagreement remained.

Statistical analysis
The pooled sOC level was compared between cases and controls. Statistical analysis was performed using Review Manager (RevMan 5.3) software. First, heterogeneity of the included studies was tested. Heterogeneous data between studies was indicated by $p \leq 0.10$ (or $I^2 \geq 50\%$), and homogeneous data was indicated by $p > 0.10$ (or $I^2 < 50\%$). A Fixed Effect model was used for homogeneous data, whereas a Random Effects model was used for heterogeneous data. Continuous variables of sOC level were reported with 95% confidence interval (95% CI) of the mean difference (MD) and $p$ value. The test of overall effect with a $p < 0.05$ was considered to be statistically significant. Collected data were carefully inputted, and then rechecked by two reviewers respectively.

Subgroup analysis according to different fragments of the sOC molecules and different regions of the study
population was also performed, with the same method mentioned above. Heterogeneous data between subgroups was indicated by $p \leq 0.10$ (or $I^2 \geq 50\%$) and homogeneous data between subgroups was indicated by $p > 0.10$ (or $I^2 < 50\%$).

**Results**

**Study selection**

Six hundred and ninety five references were identified, of which 10 studies [18–27] fulfilled all the inclusion criteria and were finally enrolled in this analysis, including 849 PMO patients and 728 postmenopausal controls (Fig. 1).

**Characteristics of included studies**

Characteristics of the included studies are summarized in Table 1. The enrolled studies were all published in English, from China (2 studies), Saudi Arabia (1 study), Korea (1 study), UK (1 study), Turkey (2 studies), France (1 study) and Spain (2 studies), including Asian and European populations. Eight studies reported the assay kits used for OC evaluation. The assay kits from Roche targeting the N-terminal mid-fragment of OC molecule (N-MID) were used in 4 studies, while the kits from DSL, Metra Biosystems and Cis-bio detecting intact OC molecules and were adopted by 1 study respectively. Information of the definite target segment of OC molecule was not provided in the instructions of the kit from Incstar. Nine out of the ten studies reported fasting blood sampling. Serum OC level was evaluated and compared between PMO and control groups in each individual study. There was no significant difference in the mean age between cases and controls in all the enrolled studies.

**Quality assessment**

Quality assessment of the included studies was summarized in Table 1. All the 10 studies scored ≥6 points and were considered of high quality.

**Outcomes**

**Overall difference in sOC level between PMO cases and controls**

Significant heterogeneity was indicated between studies ($I^2 = 100\%$). We therefore pooled the sOC level from all the included studies with Random Effects model. A trend of increased sOC level in PMO cases could be observed, while the difference in sOC level between cases
and controls was not statistically significant [MD = 1.84, 95%CI: (−1.49, 5.16), \( p = 0.28 \)] (Fig. 2).

**Subgroup analysis of the sOC level between PMO cases and controls**

Subgroup analysis according to different target fragments of OC molecules revealed no significant difference in both intact sOC [MD = 1.76, 95%CI: (−1.71, 5.23), \( p = 0.32 \)] and N-MID level [MD = 0.67, 95%CI: (−5.83, 7.18), \( p = 0.84 \)] between cases and controls (Fig. 3). Meanwhile, subgroup analysis according to different regions demonstrated a significant increased sOC level in European [MD = 3.15, 95%CI: (0.90, 5.39), \( p = 0.006 \)] but not in Asian PMO patients compared to controls [MD = −0.06, 95%CI: (−6.02, 5.89), \( p = 0.98 \)] (Fig. 4).

**Sensitivity analysis**

We removed one study at a time and re-compared the pooled sOC level between cases and controls. Significant change occurred when removing Al-Daghri’s study [27], which changed the pooled difference from [MD = 1.84, 95%CI: (−1.49, 5.16), \( p = 0.28 \)] to [MD = 2.64, 95%CI: (1.69, 3.59), \( p < 0.00001 \)]. This result indicated that the pooled test performance of this analysis could be influenced by a single study. Therefore, the conclusion should be carefully drawn and further tested.

**Discussion**

Serum OC has been widely applied to indicate bone turnover status in PMO management with several advantages such as bone specificity, non-invasiveness and dynamic-response. However, updated knowledge of OC challenges its traditional role as a bone turnover indicator in vivo, and studies have reported conflicting results of the change of sOC level in PMO cases.

PMO presents a high bone turnover rate with both increased bone resorption and formation [10–12]. Accordingly, most of the included studies (six out of ten) in our meta-analysis reported a significantly increased sOC level in PMO patients. Yet, there were also three studies reporting the same sOC level between cases and controls.

---

**Table 1** Characteristics of the included studies

| Study         | Country   | Region | Sample size | Age (years)a | Manufacturer of the OC assay kit | Targetb | Sampling condition | NOSc |
|---------------|-----------|--------|-------------|--------------|---------------------------------|---------|-------------------|------|
| Zhang 2015    | China     | Asia   | 257         | 62.73 (3.94) | Roche                           | N-MID   | NA                | 6    |
| Al-Daghri 2014| Saudi Arabia | Asia | 100         | 50.6 (8.2)   | Roche                           | N-MID   | fasting           | 9    |
| Jabbar 2011   | UK        | Europe | 185         | 62.06 (14.53)| Roche                           | N-MID   | fasting           | 9    |
| Verit 2006    | Turkey    | Europe | 45          | 55.68 (5.58) | NA                              | NA      | fasting           | 7    |
| Pouilles 2006 | France    | Europe | 60          | 52.2 (2.5)   | Roche                           | N-MID   | fasting           | 9    |
| Luo 2006      | China     | Asia   | 45          | 56.1 (4.4)   | DSL                             | intact  | fasting           | 9    |
| Duman 2004    | Turkey    | Europe | 75          | 53.16 (1.31) | NA                              | NA      | fasting           | 7    |
| Dominguez 1998| Spain     | Europe | 26          | 59 (6)       | Metra Biosystems                | intact  | fasting           | 7    |
| Kim 1996      | Korea     | Asia   | 14          | 56.2 (1.7)   | Incstar                         | NA      | fasting           | 7    |
| Diaz 1995     | Spain     | Europe | 42          | 62 (11)      | Cis-bio                         | NA      | fasting           | 7    |

**OC** osteocalcin, **N-MID** N-terminal midfragment of osteocalcin molecule, **intact** intact osteocalcin molecule, **PMO** postmenopausal osteoporosis, **NOS** Newcastle-Ottawa Scale, **NA** data not available. aAge is demonstrated with Mean (Standard deviation); bTarget fragment of the OC molecule; cRange: 1–9. Studies achieving six or more points are considered of high quality.

**Fig. 2** Forest plot of sOC level comparison between PMO patients and controls. sOC, serum osteocalcin; PMO, postmenopausal osteoporosis.
and even one study reporting a decreased sOC level in PMO cases.

The subsequent meta-analysis of all the included studies revealed only a trend of increase in sOC level in PMO cases compared to controls [95%CI: (−1.49, 5.16), \( p = 0.28 \)], which is not statistically significant. Subgroup analysis according to different regions and sOC fragments also revealed the same sOC level between cases and controls except in the European subgroup, where a significantly increased sOC level was observed in PMO patients.

By sensitivity analysis, we found that the pooled result was significantly influenced by Al-Daghri’s study [27], in which a significant decrease of sOC level was reported in PMO patients. We analyzed the Asian subgroup and found that after removal of Al-Daghri’s study, the increase of pooled sOC level in Asian PMO cases compared to Asian controls became significant (from 0.98 to 0.03), just consistent with the result found in European subgroup. Therefore, it is possible that the different results reported in the subgroup analysis was not due to regional differences, but rather resulted from the effect of Al-Daghri’s study on the Asian subgroup. However, every included study counts and we cannot ignore any study meeting the inclusion criteria yet with unexpected
result. According to previous studies, osteocalcin, once undercarboxylated (unOC), had been found to act as a hormone [28] and had a broad spectrum of interactions with glucose metabolism [29], fertility [30] and even aging [31]. In Al-Daghri’s study, the exact reason for the decreased sOC level in PMO cases remained unknown, but interactions of OC with glucose metabolism might have an effect on the result since fasting glucose levels in cases were slightly higher than controls and reached over 7.0 mmol/L (PMO vs control: 7.2 ± 3.6 vs 6.5 ± 3.2 mmol/L), indicating possible energy metabolism disorder in PMO group.

The major result of our current meta-analysis indicated no significant difference in the pooled sOC level between PMO cases and controls, which was consistent with the previous relevant meta-analysis reporting the same sOC level in osteoporotic and healthy populations in 2012 [13]. However, they included both primary (both type I and type II) and secondary osteoporosis, which might have introduced confounding factors into the analysis. In contrast, we compared only PMO cases with age and sex matched controls, in which the bone metabolic pattern was homogeneous and well clarified. Moreover, subgroup analyses according to the potential confounding factors (region of the study population and sOC fragment) were further performed. Therefore, our analysis was more specific and reliable to PMO. Besides, we have also compared the sOC levels in male population with and without OP in a previous meta-analysis and found no significant difference either [32].

However, some limitations should be mentioned in this meta-analysis. First, all the included studies were case-control studies due to the design of our research, and the level of evidence was lower than randomized controlled trials (RCTs). Second, significant heterogeneity existed between studies, which could still not be eliminated by subgroup analysis. The heterogeneity between studies might probably come from: 1. variations in the target sOC fragments evaluated by different assay kits; 2. variations in the experimental conditions [33, 34]. The intact OC molecule is rapidly degraded in serum, generating variable segments, thus limiting its utility in lab tests [35, 36]. Therefore, new techniques for sOC evaluation as well as standardization of methodologies and experimental conditions are urged for better application of sOC. Third, due to limited information from the included studies, physical activity levels could not be considered for variable control in our analysis, which could also have an effect on bone remodeling. However, there might not be a significant difference in physical activity levels in the senile postmenopausal populations between PMO cases and controls as long as the age and postmenopausal status were matched. Last but not least, the carboxylation status of sOC was not mentioned in any of the included studies. As a matter of fact, both OC and unOC in the circulation have been reported to correlate with each other [37, 38] and with bone quality [39, 40] but most of the conventional sOC assay kits are designed for total sOC while unOC can only be evaluated with special techniques [41, 42]. The result of this meta-analysis might not be significantly influenced by the carboxylation status of sOC as the same OC assay kit was adopted in PMO and control groups within each individual study.

Conclusions
Based on the current available evidence, there is no significant difference of the pooled sOC level in PMO cases compared to postmenopausal controls. Since OC molecules are quite heterogeneous (different carboxylation status and different fragments) in the circulation and can be influenced by multiple metabolic events, sOC is not a good indicator for the high bone turnover status in PMO unless novel techniques for standardized circulatory sOC evaluation are applied in the future. Despite our rigorous methodology, the level of available evidence can still be improved with further high quality studies.

Abbreviations
CI: Confidence interval; MD: Mean difference; N-MID: N-terminal mid-fragment of OC molecule; NOS: Newcastle-Ottawa Scale; OC: Osteocalcin; PMO: Postmenopausal osteoporosis; PRISMA: Preferred Reporting Item for Systemic Review and Meta-analysis; RCTs: Randomized controlled trials; sOC: serum osteocalcin

Acknowledgments
Not applicable.

Authors’ contributions
LMR, JWD and ZYL had full access to all the data in the study and accept responsibility for the integrity and accuracy of the data analysis. LMR and ZYL made substantial contributions to the conception and design of the study, ZYL, YTJ and YY contributed in acquisition, analysis and interpretation of data. ZYL, YTJ, LH and CXL participated in drafting the manuscript. MD and RQC substantially contributed to the revision of the manuscript. All authors revised the manuscript critically for important intellectual content and approved the final version of the submitted manuscript.

Funding
This study was funded by the National Natural Science Foundation of China (No. 8177090663). The funding body played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.
References

1. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24(1):23–57.
2. Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol. 2011;6:21–45.
3. Jackson RD, Mysiw WJ. Insights into the epidemiology of postmenopausal osteoporosis: the Women's Health Initiative. Semin Reprod Med. 2014;32(6):454–62.
4. Haushka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev. 1989;69(3):990–1047.
5. Singer FR, Eyre DR. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med. 2008;75(10):739–50.
6. Ivaska KK, Hentunen TA, Vaaniemi J, Ylipahkala H, Pettersson K, Vaananen HK. Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem. 2004;279(18):18361–9.
7. Burch J, Rice S, Yang H, Neilson A, Stik L, Francis R, Holloway P, Selby P, Craig D. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. Health Technol Assess. 2014;18(11):1–180.
8. Park SG, Jeong SU, Lee JH, Ryu SH, Jeong HJ, Sim YJ, Kim DK, Kim GC. The changes of CTX, DPD, Osteocalcin, and bone mineral density during the postmenopausal period. Ann Rehabil Med. 2018;42(3):341–8.
9. Boyacioglu O, Orenay-Boyacioglu S, Yildirim H, Korkmaz M. Boren intake, osteocalcin polymorphism and serum level in postmenopausal osteoporosis. J Trace Elem Med Biol. 2018;48:52–6.
10. Erikson EF, Hodgson SF, Eastell R, Cedel SL, O'Fallon WM, Riggs BL. Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J Bone Miner Res. 1990;5(4):311–9.
11. Garnero P, Somay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11(3):337–49.
12. Raiz L. Pathogenesis of osteoporosis: conflicts, conflicts, and prospects. J Clin Invest. 2005;115(11):3318–25.
13. Biver E, Chopin F, Caffier G, Benatson TF, Bouard V, Garnero P, Cortet B. Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosis. Joint Bone Spine. 2012;79(1):20–5.
14. Panic N, Leoncini E, de Belvis G, Ricciardi W, Bocca S. Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS One. 2013;8(12):e83138.
15. Mohler D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(S):336–41.
16. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994;4(6):368–81.
17. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(6):603–5.
18. Jabbir S, Drury J, Fordham JN, Datta HK, Francis RM, Tuck SP. Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. J Clin Pathol. 2011;64(4):354–7.
19. Herit FF, Geyikli Y, Yagan P, Celik A. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis. Arch Gynecol Obstet. 2006;274(3):133–7.
20. Pouilles JM, Tremolieres FA, Ribot C. Osteoporosis in otherwise healthy perimenopausal and early postmenopausal women: physical and biochemical characteristics. Osteoporos Int. 2006;17(1):193–200.
21. Luo XH, Guo L, Shan PF, Xie H, Wu XP, Zhang H, Cao XZ, Yuan LQ, Liao EY. Relationship of circulating MMP-2, MMP-1, and TIMP-1 levels with bone biochemical markers and bone mineral density in postmenopausal Chinese women. Osteoporos Int. 2006;17(4):521–6.
22. Duman BS, Tanakol R, Erensosy N, Ozturk M, Yilmazer S. Vitamin D receptor allelic, bone mineral density and turnover in postmenopausal osteoporotic and healthy women. Med Princ Pract. 2004;13(5):260–6.
23. Dominguez CC, Sosa HM, Traba ML, Alvarez VE, de la Piedra C. Biochemical markers of bone formation in the study of postmenopausal osteoporosis. Osteoporos Int. 1998;8(2):147–51.
24. Kim JG, Lee JY. Serum insulin-like growth factor binding protein profiles in postmenopausal women: their correlation with bone mineral density. Am J Obstet Gynecol. 1996;174(5):1511–7.
25. Daz DE, Diaz MM, de la Piedra C, Rapado A. Lack of correlation between levels of osteocalcin and bone alkaline phosphatase in healthy control and postmenopausal osteoporotic women. Horm Metab Res. 1995;27(3):151–4.
26. Zhang Y, Feng E, Xu Y, Wang W, Zhang T, Xiao L, Chen R, Lin Y, Chen D, Lin L, et al. Serum Sema4D levels are associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis. Int J Clin Exp Med. 2015;8(9):16352–7.
27. Al-Daghri NM, Yakout S, Al-Shehri E, Al-Fawaz H, Aljohani N, Al-Saleh Y. Inflammatory and bone turnover markers in relation to PTH and vitamin D status among Saudi postmenopausal women with and without osteoporosis. Int J Clin Exp Med. 2014;7(9):2812–9.
28. Wei J, Karsenty G. An overview of the metabolic functions of osteocalcin. Curt Osteoporos Rep. 2015;13(3):180–5.
29. Ferron M, Wei J, Yoshizawa T, Del Fattore A, DePinho RA, Teti A, Dacy P, Karsenty G. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. Cell. 2010;142(2):296–308.
30. Oury F, Ferron M, Huizelen W, Confavreux C, Xu L, Lacombe J, Sinivas P, Chamouni A, Lugani F, Lejeune H, et al. Osteocalcin regulates murine and human fertility through a pancreas-bone-testis axis. J Clin Invest. 2013;123(6):2421–33.
31. Oury F. A crosstalk between bone and gonads. Ann N Y Acad Sci. 2012;1260:1–7.
32. Liu ZY, Yang Y, Wen CY, Rong LM. Serum Osteocalcin and testosterone concentrations in adult males with or without primary osteoporosis: a Meta-analysis. Biomed Res Int. 2017;2017:982048.
33. Lee AJ, Hodges S, Eastell R. Measurement of osteocalcin. Ann Clin Biochem. 2000;37(Pt 4):342–46.
34. Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev. 1996;17(4):333–68.
35. Coates P. Bone turnover markers: Aust Fam Physician. 2013;42(2):285–7.
36. Garnero P, Grimaux M, Seguin P, Delmas PD. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res. 1994;9(2):255–64.
37. Booth SL, Centi A, Smith SR, Gundberg C. The role of osteocalcin in human glucose metabolism: marker or mediator? Nat Rev Endocrinol. 2013;9(1):43–55.
38. Liu DM, Guo XZ, Tong HJ, Tao B, Sun LH, Zhao HY, Ning G, Liu JM. Association between osteocalcin and glucose metabolism: a meta-analysis. Osteoporos Int. 2015;26(12):2882–33.
39. Suzuki Y, Maruyama-Nagao A, Sakuraba K, Kawai S. Level of serum undecarboxylated osteocalcin correlates with bone quality assessed by calcaneal quantitative ultrasound sonometry in young Japanese females. Exp Ther Med. 2017;13(5):1937–43.
40. Zhang XY, He JW, Fu WZ, Liu YJ, Zhang ZL. Associations of serum osteocalcin and polymorphisms of the Osteocalcin gene with bone mineral density in postmenopausal and elderly Chinese women. J Nutrigenet Nutrigenomics. 2016;9(5–6):231–42.
41. Nagata Y, Inaba M, Ishimashii Y, Okazaki H, Yamada S, Mori K, Sajiyo S, Koyama H, Okuno S. Increased undecarboxylated osteocalcin/Intact osteocalcin ratio in patients undergoing hemodialysis. Osteoporos Int. 2015;26(3):1053–61.
42. Gundberg CM, Lian JB, Booth SL. Vitamin K-dependent carboxylation of osteocalcin: friend or foe? Advances in nutrition (Bethesda, Md). 2012;3(2):149–57.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.